| scholarly article | Q13442814 |
| P2093 | author name string | Spoorenberg A | |
| van der Heijde D | |||
| Dougados M | |||
| Mielants H | |||
| Landewé R | |||
| van Tubergen A | |||
| Heuft-Dorenbosch L | |||
| van ver Tempel H | |||
| P2860 | cites work | Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study | Q74602875 |
| Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV | Q77403529 | ||
| Classification of inflammatory arthritis by enthesitis | Q77498550 | ||
| Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial | Q28214774 | ||
| A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index | Q28299001 | ||
| Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug | Q32045021 | ||
| Enthesitis in spondyloarthropathy | Q33690425 | ||
| Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis | Q33860755 | ||
| Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis | Q41159020 | ||
| Enthesopathy of rheumatoid and ankylosing spondylitis | Q41293713 | ||
| Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. | Q64979798 | ||
| Plantar fasciitis and Achilles tendinitis among 150 cases of seronegative spondarthritis | Q70708342 | ||
| An update on the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDAI, BASFI): excellent Cronbach's alpha scores | Q71707688 | ||
| Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy | Q72079210 | ||
| Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis | Q72851561 | ||
| Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? | Q73069514 | ||
| Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group | Q73893294 | ||
| The OMERACT filter for Outcome Measures in Rheumatology | Q74267048 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enthesitis | Q3055079 |
| P304 | page(s) | 127-132 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Assessment of enthesitis in ankylosing spondylitis | |
| P478 | volume | 62 |
| Q95359159 | Q95359159 |
| Q95359600 | Q95359600 |
| Q92219713 | A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis |
| Q37325983 | A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis |
| Q83206200 | A modified juvenile arthritis damage index to improve articular damage assessment in juvenile idiopathic arthritis--enthesitis-related arthritis (JIA-ERA) |
| Q36584217 | A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis |
| Q38236514 | A review of disease activity measures for psoriatic arthritis: what is the best approach? |
| Q35953484 | A sonographic enthesitic index of lower limbs is a valuable tool in the assessment of ankylosing spondylitis |
| Q37172795 | Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial |
| Q42680443 | Adalimumab: in non-radiographic axial spondyloarthritis |
| Q93584084 | Advances in Muscles, Ligaments and Tendons: Research and Clinical Practice |
| Q93559145 | Advances in Muscles, Ligaments and Tendons:: November 26–27, 2011, Rome, Campus X Tor Vergata |
| Q58417373 | An open-label study of zoledronic acid (Aclasta 5 mg iv) in the treatment of ankylosing spondylitis |
| Q88013479 | Ankylosing spondylitis monocyte-derived macrophages express increased level of A2A adenosine receptor and decreased level of ectonucleoside triphosphate diphosphohydrolase-1 (CD39), A1 and A2B adenosine receptors |
| Q36084884 | Anterior chest wall inflammation by whole-body magnetic resonance imaging in patients with spondyloarthritis: lack of association between clinical and imaging findings in a cross-sectional study |
| Q43195995 | Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis |
| Q37741879 | Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice |
| Q55316418 | Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. |
| Q36968787 | Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) |
| Q57052185 | Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort |
| Q82520693 | Assessment of enthesitis in ankylosing spondylitis by power Doppler ultrasonography |
| Q48054896 | Back/joint pain, illness perceptions and coping are important predictors of quality of life and work productivity in patients with inflammatory bowel disease: a 12-month longitudinal study |
| Q87600788 | C-reactive protein gene and Toll-like receptor 4 gene polymorphisms can relate to the development of psoriatic arthritis |
| Q46689579 | Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis |
| Q26866120 | Clinical Tools to Assess and Monitor Spondyloarthritis |
| Q35687813 | Clinical and ultrasound examination of the leeds enthesitis index in psoriatic arthritis and rheumatoid arthritis. |
| Q37601570 | Clinical assessment and outcome research in spondyloarthritis |
| Q37267600 | Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study |
| Q42591077 | Clinical examination or whole-body magnetic resonance imaging: the Holy Grail of spondyloarthritis imaging |
| Q26995307 | Clinical outcomes in psoriatic arthritis: A systematic literature review |
| Q37031662 | Clinical potential of apremilast in the treatment of psoriatic arthritis |
| Q37601557 | Clinical utility of ultrasonography in spondyloarthropathies |
| Q62111135 | Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment |
| Q41588445 | Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi |
| Q40824928 | Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study |
| Q45956997 | Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). |
| Q50879886 | Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors. |
| Q48132271 | Correlations among enthesitis, clinical, radiographic and quality of life parameters in patients with ankylosing spondylitis. |
| Q64083735 | Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort |
| Q57605596 | DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen |
| Q84311215 | Decreased heart rate variability in patients with psoriatic arthritis |
| Q80462005 | Defining disease status in ankylosing spondylitis: validation and cross-cultural adaptation of the Arabic Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Bath Ankylosing |
| Q53065937 | Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP. |
| Q58694922 | Detection of high cardiovascular risk patients with ankylosing spondylitis based on the assessment of abdominal aortic calcium as compared to carotid ultrasound |
| Q40687378 | Developing the Thai Siriraj Psoriatic Arthritis Screening Tool and validating the Thai Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire. |
| Q36960227 | Diagnosing early ankylosing spondylitis |
| Q35210214 | Diagnosis and treatment of enthesitis |
| Q41858221 | Diagnosis and treatment of enthesitis-related arthritis |
| Q36270343 | Diagnositic value of pelvic enthesitis on MRI of the sacroiliac joints in enthesitis related arthritis |
| Q49104393 | Diagnostic value of pelvic enthesitis on MRI of the sacroiliac joints in spondyloarthritis |
| Q53114781 | Differences between women and men with recent-onset axial spondyloarthritis: results from a prospective multicenter French cohort. |
| Q48507695 | Different ethnic background is associated with distinct clinical profiles in the spondyloarthritides in the North and South of Brazil |
| Q39874212 | Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial |
| Q33993099 | Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice |
| Q42176257 | Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study |
| Q53176284 | Early-stage hip involvement in patients with ankylosing spondylitis: A Chinese study based on magnetic resonance imaging. |
| Q37036355 | Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial |
| Q34027624 | Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy |
| Q33923298 | Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis |
| Q35537104 | Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial |
| Q38993324 | Efficacy and safety of adalimumab in ankylosing spondylitis |
| Q36876679 | Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). |
| Q41311218 | Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study |
| Q46467386 | Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial |
| Q33659249 | Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas |
| Q50906224 | Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. |
| Q40705952 | Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). |
| Q41827680 | Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study |
| Q90355990 | Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2 |
| Q30745189 | Enteropathic arthritis in Brazil: data from the Brazilian Registry of Spondyloarthritis. |
| Q48726959 | Enthesitis and its relationships with disease parameters in Moroccan patients with ankylosing spondylitis |
| Q39745756 | Enthesitis in an inception cohort of enthesitis-related arthritis |
| Q90232146 | Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management |
| Q38056331 | Enthesitis in psoriatic disease |
| Q48922156 | Enthesitis of lumbar spinal ligaments in clinically suspected spondyloarthritis: value of gadolinium-enhanced MR images in comparison to STIR. |
| Q47329414 | Enthesitis: from pathophysiology to treatment |
| Q41102166 | Enthesopathy - a personal perspective on its manifestations, implications and treatment |
| Q41412218 | Erectile dysfunction in ankylosing spondylitis patients |
| Q61895141 | Espondiloartritis. Concepto. Clasificación. Etiopatogenia. Formas clínicas. Criterios diagnósticos |
| Q37438552 | Evaluation and Treatment of Enthesitis-Related Arthritis |
| Q59123650 | Evaluation of spinal mobility measurements in predicting axial psoriatic arthritis |
| Q34608115 | Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study |
| Q92505093 | Fatty corner lesions in T1-weighted magnetic resonance imaging as an alternative to sacroiliitis for diagnosis of axial spondyloarthritis |
| Q33408102 | First signs and symptoms of spondyloarthritis--data from an inception cohort with a disease course of two years or less (REGISPONSER-Early) |
| Q48510796 | Gender characterization in a large series of Brazilian patients with spondyloarthritis |
| Q37530561 | Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort |
| Q40651714 | Gender specific differences in patients with psoriatic arthritis |
| Q46585904 | Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial |
| Q36032569 | Guideline for anti-TNF-alpha therapy in psoriatic arthritis |
| Q39091677 | Health-related quality of life in Moroccan patients with ankylosing spondylitis. |
| Q38246381 | Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review |
| Q38223722 | How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review |
| Q64103867 | Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study |
| Q37427257 | Inflammatory arthritis: an overview for primary care physicians |
| Q94397565 | Interleukin inhibitors for psoriatic arthritis |
| Q48090905 | Is the health-related quality of life and functional status of patients with psoriatic arthritis worse than that of patients with psoriasis alone? |
| Q45296475 | Is there subclinical enthesitis in early psoriatic arthritis? A clinical comparison with power doppler ultrasound |
| Q57292306 | Is ultrasonographic enthesitis evaluation helpful for diagnosis of non-radiographic axial spondyloarthritis? |
| Q91937115 | Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis |
| Q37423289 | Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability |
| Q51120969 | Magnetic resonance imaging of pelvic entheses--a systematic comparison between short tau inversion recovery (STIR) and T1-weighted, contrast-enhanced, fat-saturated sequences. |
| Q41454181 | Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. |
| Q36439889 | Management and evaluation of extra-articular manifestations in spondyloarthritis |
| Q36520126 | Measuring disease activity in psoriatic arthritis |
| Q36542790 | Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study |
| Q94336562 | Methotrexate for psoriatic arthritis |
| Q52733222 | Modification of a sonographic enthesitis score to differentiate between psoriatic arthritis and young healthy volunteers. |
| Q35688981 | New directions in classification and outcome assessment in ankylosing spondylitis |
| Q38005057 | Non-orthopaedic causes of shoulder pain: what the shoulder expert must remember |
| Q38211315 | Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials |
| Q82732857 | Osteoporosis in psoriatic arthritis: is there any? |
| Q36140811 | Outcome measures in psoriatic arthritis |
| Q36208083 | Outcome measures in psoriatic arthritis clinical trials |
| Q52549412 | Outcome measures of disease activity in inflammatory arthritis. |
| Q40401248 | Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: the DESIR cohort |
| Q34803148 | Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial |
| Q48581744 | Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis |
| Q46876696 | Pattern of bone erosion and bone proliferation in psoriatic arthritis hands: a high-resolution computed tomography and radiography follow-up study during adalimumab therapy |
| Q43943666 | Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort |
| Q53100337 | Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. |
| Q87157614 | Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy |
| Q44033146 | Performance of ultrasounds compared with radiographs to detect chronic enthesitis signs in patients with ankylosing spondylitis. |
| Q34174214 | Predictors of functional deterioration in Chinese patients with psoriatic arthritis: a longitudinal study |
| Q41073598 | Prevalence of Psoriatic Arthritis in Primary Care Patients With Psoriasis |
| Q35579462 | Psoriatic arthritis assessment tools in clinical trials |
| Q44557662 | Psoriatic arthritis. Treatment outcome parameters |
| Q90621586 | Pulmonary Function, Aerobic Capacity and Related Variables in Patients With Ankylosing Spondylitis |
| Q53060690 | Quality of life and related variables in patients with ankylosing spondylitis. |
| Q35535807 | Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis |
| Q79190255 | Relationship between the severity of enthesitis and clinical and laboratory parameters in patients with ankylosing spondylitis |
| Q41687161 | Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort |
| Q37541327 | Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment |
| Q38903129 | Secukinumab: a promising therapeutic option in spondyloarthritis |
| Q50497179 | Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. |
| Q55042107 | Serum IL-6 correlates with axial mobility index (Bath Ankylosing Spondylitis Metrology Index) in Brazilian patients with ankylosing spondylitis. |
| Q48018975 | Sleep quality in patients with psoriatic arthritis |
| Q44429588 | Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index in Turkish patients with ankylosing spondylitis: relationship with disease activity and quality of life |
| Q30361133 | Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic study |
| Q40634737 | Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study |
| Q42176263 | Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study |
| Q53089035 | Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. |
| Q24240905 | TNF-alpha inhibitors for psoriatic arthritis |
| Q87807672 | Tailored approach to early psoriatic arthritis patients: clinical and ultrasonographic predictors for structural joint damage |
| Q34630959 | The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis |
| Q36925535 | The assessment of ankylosing spondylitis in clinical practice. |
| Q92737173 | The colon and terminal ileum in patients with ankylosing spondylitis and controls in Bangladesh: a macroscopic and microscopic study |
| Q50718510 | The enthesopathy of celiac patients: effects of gluten-free diet. |
| Q50881713 | The occurrence of lower limb enthesopathy in coeliac disease patients without clinical signs of articular involvement. |
| Q36940942 | The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. |
| Q51676873 | The relationship between enthesitis indices and disease activity parameters in patients with ankylosing spondylitis. |
| Q37976646 | The role of Doppler ultrasound in rheumatic diseases. |
| Q55690278 | Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies. |
| Q90393887 | To what extend is nail ultrasound discriminative between psoriasis, psoriatic arthritis and healthy subjects? |
| Q37608920 | Tools for monitoring spondyloarthritis in clinical practice |
| Q47187728 | Translation, cultural adaptation, and validation of the Bath questionnaires and HAQ-S in Hindi for Indian patients with ankylosing spondylitis |
| Q90236321 | Treating psoriatic arthritis to target: discordance between physicians and patients' assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort |
| Q37465518 | Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force |
| Q92382260 | Turkish Version of Evaluation of Ankylosing Spondylitis Quality of Life Questionnaire in Patients With Ankylosing Spondylitis: A Validation and Reliability Study |
| Q45996999 | Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. |
| Q41867715 | Ultrasonographic evaluation of enthesitis in patients with ankylosing spondylitis |
| Q50920770 | Ultrasonographic evaluation of femoral cartilage thickness in patients with psoriatic arthritis. |
| Q38710246 | Ultrasonography assessment of heel entheses in patients with spondyloarthritis: a comparative study with magnetic resonance imaging and conventional radiography |
| Q87466451 | Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate |
| Q43482755 | Ultrasound evaluation of greater trochanter pain syndrome in patients with spondyloarthritis: are there any specific features? |
| Q34993041 | Ultrasound features of shoulder involvement in patients with ankylosing spondylitis: a case-control study |
| Q82125765 | Ultrasound revealing subclinical enthesopathy at the greater trochanter level in patients with spondyloarthritis |
| Q53119881 | Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? |
| Q37598921 | Update on juvenile spondyloarthritis |
| Q38438153 | Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). |
| Q83188939 | [Ankylosing spondylitis. Target treatment criteria] |
| Q83155701 | [Cross-sectional imaging of peripheral involvement in ankylosing spondylitis] |
| Q84600024 | [Effectiveness of biological agents in ankylosing spondylitis] |
| Q84600088 | [Enthesis as a target element in spondylarthritides] |
| Q56966667 | [Enthesitis in connection with spondyloarthritides] |
| Q52870418 | [Enthesitis in the context of spondyloarthritides]. |
| Q82663598 | [Outcome parameters for use in psoriatic arthritis] |
| Q85054900 | [Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy] |
| Q26862017 | Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds En |
Search more.